Largest pharmaceutical companies in the United States by total liabilities
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
AbbVie leads the 44 pharmaceutical companies in the United States ranked by total liabilities, at AED 503.8B, ahead of Pfizer (AED 445.8B) and Johnson & Johnson (AED 432.1B). Figures as of 20 Nov 2026, 04:26 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 44
- First
- AbbVieAED 503.8B
- Median
- AED 3.1B
- Combined market value
- AED 13.72T
- Countries
- 1
Market values as of .
United States▾
All sectors▾
Pharmaceuticals▾
| # | Company | Total liabilities ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AbbVieABBV · Health Care | AED 503.8B | AED 1.84T | AED 1,041.27 | 0.86% down | 25% up | ||
| 2 | PfizerPFE · Health Care | AED 445.8B | AED 576.5B | AED 101.14 | 1.85% down | 15% up | ||
| 3 | Johnson & JohnsonJNJ · Health Care | AED 432.1B | AED 2.36T | AED 981.04 | 2.04% down | 34% up | ||
| 4 | Eli LillyLLY · Health Care | AED 315.6B | AED 4.42T | AED 4,961.85 | 2.29% down | 33% up | ||
| 5 | Merck & CoMRK · Health Care | AED 309.2B | AED 1.2T | AED 487.73 | 3.61% down | 45% up | ||
| 6 | Bristol-Myers SquibbBMY · Health Care | AED 262.7B | AED 437.9B | AED 214.25 | 2.05% down | 30% up | ||
| 7 | Abbott LaboratoriesABT · Health Care | AED 124.6B | AED 660.7B | AED 381.45 | 0.58% down | 16% down | ||
| 8 | ViatrisVTRS · Health Care | AED 82.6B | AED 83.7B | AED 73.01 | 1.97% down | 99% up | ||
| 9 | ZoetisZTS · Health Care | AED 44.6B | AED 120.6B | AED 296.69 | 5.59% down | 26% down | ||
| 10 | Royalty PharmaRPRX · Health Care | AED 36.4B | AED 143B | AED 248.69 | 1.38% down | 79% up | ||
| 11 | Regeneron PharmaceuticalsREGN · Health Care | AED 34.2B | AED 350.8B | AED 3,390.87 | 2.35% down | 28% up | ||
| 12 | Vertex PharmaceuticalsVRTX · Health Care | AED 25.6B | AED 484.8B | AED 1,912.07 | 2.94% down | 27% up | ||
| 13 | Elanco Animal HealthELAN · Health Care | AED 25B | AED 48.3B | AED 96.55 | 1.54% down | 26% up | ||
| 14 | Alnylam PharmaceuticalsALNY · Health Care | AED 15.3B | AED 72.7B | AED 542.85 | 1.06% down | 66% down | ||
| 15 | Amneal PharmaceuticalsAMRX · Health Care | AED 13.5B | AED 27.4B | AED 78.55 | 2.24% down | 90% up | ||
| 16 | PTC TherapeuticsPTCT · Health Care | AED 11.4B | AED 17.9B | AED 214.19 | 3.16% down | 21% down | ||
| 17 | Ionis PharmaceuticalsIONS · Health Care | AED 11.1B | AED 16.6B | AED 99.96 | 0.62% down | 63% down | ||
| 18 | BridgeBio PharmaBBIO · Health Care | AED 11.1B | AED 55.9B | AED 287.11 | 0.22% up | 21% up | ||
| 19 | CytokineticsCYTK · Health Care | AED 7.7B | AED 26.3B | AED 188.98 | 0.27% up | 19% down | ||
| 20 | InsmedINSM · Health Care | AED 5.6B | AED 116.4B | AED 530.51 | 20.58% up | 40% down | ||
| 21 | BioMarin PharmaceuticalBMRN · Health Care | AED 5.5B | AED 43.7B | AED 225.56 | 0.02% down | 17% up | ||
| 22 | Arrowhead PharmaceuticalsARWR · Health Care | AED 3.2B | AED 22.7B | AED 160.30 | 1.25% up | 13% up | ||
| 23 | United TherapeuticsUTHR · Health Care | AED 2.9B | AED 87.4B | AED 2,053.24 | 3.16% down | 22% up | ||
| 24 | Legend BiotechLEGN · Health Care | AED 2.7B | AED 11.5B | AED 59.13 | 0.92% down | 41% down | ||
| 25 | Madrigal PharmaceuticalsMDGL · Health Care | AED 2.4B | AED 33.8B | AED 1,456.99 | 0.34% down | 27% down | ||
| 26 | Axsome TherapeuticsAXSM · Health Care | AED 2.2B | AED 26.2B | AED 498.27 | 1.25% up | 6% down | ||
| 27 | Ligand PharmaceuticalsLGND · Health Care | AED 2B | AED 21.1B | AED 1,053.76 | 3.94% down | 50% up | ||
| 28 | Mirum PharmaceuticalsMIRM · Health Care | AED 1.9B | AED 22.9B | AED 350.75 | 3.27% up | 34% up | ||
| 29 | Travere TherapeuticsTVTX · Health Care | AED 1.8B | AED 17B | AED 177.38 | 3.86% down | 45% up | ||
| 30 | TG TherapeuticsTGTX · Health Care | AED 1.5B | AED 36B | AED 238.27 | 1.88% down | 117% up | ||
| 31 | Cogent BiosciencesCOGT · Health Care | AED 1.1B | AED 17.7B | AED 101.87 | 0.25% down | 20% down | ||
| 32 | Rhythm PharmaceuticalsRYTM · Health Care | AED 771.8M | AED 29.7B | AED 428.94 | 1.88% down | 18% up | ||
| 33 | Corcept TherapeuticsCORT · Health Care | AED 693.5M | AED 26.1B | AED 238.63 | 4.15% down | 10% down | ||
| 34 | Definium TherapeuticsDFTX · Health Care | AED 395.8M | AED 14.8B | AED 108.26 | 1.24% up | 168% up | ||
| 35 | Summit TherapeuticsSMMT · Health Care | AED 339M | AED 31B | AED 38.82 | 0.67% up | 36% down | ||
| 36 | ErascaERAS · Health Care | AED 260.7M | AED 18.3B | AED 52.22 | 3.34% up | 395% up | ||
| 37 | Spyre TherapeuticsSYRE · Health Care | AED 229.7M | AED 34B | AED 358.54 | 3.77% down | 332% up | ||
| 38 | Praxis Precision MedicinesPRAX · Health Care | AED 219.5M | AED 31.9B | AED 1,141.75 | 1.87% up | 86% up | ||
| 39 | Protagonist TherapeuticsPTGX · Health Care | AED 196.4M | AED 29.7B | AED 455.45 | 2.47% down | 51% up | ||
| 40 | Dianthus TherapeuticsDNTH · Health Care | AED 137.8M | AED 17.5B | AED 311.53 | 1.01% up | 108% up | ||
| 41 | Edgewise TherapeuticsEWTX · Health Care | AED 111.4M | AED 16.6B | AED 151.19 | 0.48% down | 86% up | ||
| 42 | Oruka TherapeuticsORKA · Health Care | AED 61.3M | AED 24.3B | AED 358.32 | 1.91% up | 255% up | ||
| 43 | Belite BioBLTE · Health Care | AED 37M | AED 22.5B | AED 554.61 | 3.33% down | 43% up | ||
| 44 | VeradermicsMANE · Health Care | AED 33.6M | AED 19.3B | AED 456.81 | 0.38% down | 231% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total liabilities is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Where a company reports no total-liabilities line, it is worked out as assets less equity. Sums are converted from US dollars at today's exchange rate (1 USD = 3.6724 AED).
Questions and answers
Which pharmaceutical companies in the United States rank first by total liabilities?
AbbVie (AED 503.8B), Pfizer (AED 445.8B) and Johnson & Johnson (AED 432.1B) are the top three of the 44 pharmaceutical companies in the United States ranked by total liabilities as of 20 Nov 2026, 04:26 UTC.
How many pharmaceutical companies in the United States are in this ranking?
44 are ranked by total liabilities.
What are these pharmaceutical companies in the United States worth together?
The 44 pharmaceutical companies in the United States ranked by total liabilities have a combined market value of AED 13.72T as of 20 Nov 2026, 04:26 UTC.
What does ranking by total liabilities measure?
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest pharmaceutical companies in the United States by total liabilities”, data as of 20 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?country=united-states&by=total-liabilities
Underlying data: Yahoo Finance; SEC EDGAR.